Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis

被引:1
|
作者
Benlidayi, Ilke Coskun [1 ]
Basaran, Sibel [1 ]
Evlice, Ahmet [2 ]
Erdem, Miray [2 ]
Demirkiran, Meltem [2 ]
机构
[1] Cukurova Univ, Tip Fak, Fiziksel Tip Rehabilitasyon Anabilim Dali, Adana, Turkey
[2] Cukurova Univ, Tip Fak, Norol Anabilim Dali, Adana, Turkey
来源
TURK OSTEOPOROZ DERGISI-TURKISH JOURNAL OF OSTEOPOROSIS | 2015年 / 21卷 / 02期
关键词
Bisphosphonate; multiple sclerosis; osteoporosis;
D O I
10.4274/tod.88709
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to evaluate the effectiveness of bisphosphonates in osteoporotic patients with multiple sclerosis. Materials and Methods: Patients with multiple sclerosis, who were started on treatment with a diagnosis of osteoporosis, at the Department of Physical Medicine and Rehabilitation, Faculty of Medicine Cukurova University, between January 2011 and January 2014, were included in this study. Patients were allocated into control (calcium-vitamin D alone) and active treatment (calcium-vitamin D and bisphosphonate) groups according to their medications. Response to the 12-month treatment in terms of bone mineral density (BMD) values and biological marker levels were evaluated, both within and between groups. Results: The study group consisted of 29 patients (14 controls and 15 active treatment). Evaluation performed within each group revealed no significant difference between baseline and post-treatment values of BMD and biological markers in controls. However, regarding the active treatment group, a significant increase in L1-L4 T-score and 25(OH) D was detected. When delta values were taken into account, comparison between groups revealed no significant difference in terms of BMD and biological marker levels. Conclusion: The effect of calcium-vitamin D alone on BMD and biologic markers was similar to that of calcium- vitamin D and bisphosphonate combination, in multiple sclerosis patients with osteoporosis. However, prospective, randomized, controlled studies are required on this issue.
引用
收藏
页码:53 / 57
页数:5
相关论文
共 50 条
  • [31] Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis
    P. J. Voss
    D. Steybe
    P. Poxleitner
    R. Schmelzeisen
    C. Munzenmayer
    H. Fuellgraf
    A. Stricker
    W. Semper-Hogg
    Odontology, 2018, 106 : 469 - 480
  • [32] Safety and Efficacy of Fingolimod in Treatment-Naive Multiple Sclerosis Patients
    Marriott, James J.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 43 - 50
  • [33] Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
    Wang, Li
    Qi, Chun-Hui
    Zhong, Ren
    Yuan, Chao
    Zhong, Qiu-Yue
    MEDICINE, 2018, 97 (08)
  • [34] Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis
    Voss, P. J.
    Steybe, D.
    Poxleitner, P.
    Schmelzeisen, R.
    Munzenmayer, C.
    Fuellgraf, H.
    Stricker, A.
    Semper-Hogg, W.
    ODONTOLOGY, 2018, 106 (04) : 469 - 480
  • [35] Bisphosphonates, a new treatment for glucocorticoid-induced osteoporosis in children
    Noguera, A
    Ros, JB
    Pavía, C
    Alcover, E
    Valls, C
    Villaronga, M
    González, E
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2003, 16 (04) : 529 - 536
  • [36] Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal Osteoporosis
    Bilezikian, John P.
    AMERICAN JOURNAL OF MEDICINE, 2009, 122 (02) : 14 - 21
  • [37] Osteoporosis and fracture in Multiple Sclerosis - underestimated and ignored?
    Zimmermann, Olga
    Stuerner, Klarissa Hanja
    OSTEOLOGIE, 2019, 28 (04) : 259 - 267
  • [38] New bisphosphonates for the treatment of osteoporosis: Concerns and hopes
    Reginster, JY
    REVUE DU RHUMATISME, 1996, 63 (7-8): : 461 - 464
  • [39] Novel formulations of oral bisphosphonates in the treatment of osteoporosis
    Nicholas Fuggle
    Nasser Al-Daghri
    Olivier Bock
    Jaime Branco
    Olivier Bruyère
    Enrique Casado
    Etienne Cavalier
    Bernard Cortet
    Maarten de Wit
    Andrea Giusti
    Philippe Halbout
    Nicholas C. Harvey
    Mickaël Hiligsmann
    Jean-Marc Kaufman
    Andreas Kurth
    Stefania Maggi
    Radmila Matijevic
    Salvatore Minisola
    Santiago Palacios
    Régis Pierre Radermecker
    Friederike Thomasius
    Sansin Tuzun
    Nicola Veronese
    John A. Kanis
    Jean-Yves Reginster
    René Rizzoli
    Cyrus Cooper
    Aging Clinical and Experimental Research, 2022, 34 : 2625 - 2634
  • [40] Novel formulations of oral bisphosphonates in the treatment of osteoporosis
    Fuggle, Nicholas
    Al-Daghri, Nasser
    Bock, Olivier
    Branco, Jaime
    Bruyere, Olivier
    Casado, Enrique
    Cavalier, Etienne
    Cortet, Bernard
    de Wit, Maarten
    Giusti, Andrea
    Halbout, Philippe
    Harvey, Nicholas C.
    Hiligsmann, Mickael
    Kaufman, Jean-Marc
    Kurth, Andreas
    Maggi, Stefania
    Matijevic, Radmila
    Minisola, Salvatore
    Palacios, Santiago
    Radermecker, Regis Pierre
    Thomasius, Friederike
    Tuzun, Sansin
    Veronese, Nicola
    Kanis, John A.
    Reginster, Jean-Yves
    Rizzoli, Rene
    Cooper, Cyrus
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2022, 34 (11) : 2625 - 2634